1. Home
  2. ENSG vs PRAX Comparison

ENSG vs PRAX Comparison

Compare ENSG & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Ensign Group Inc.

ENSG

The Ensign Group Inc.

HOLD

Current Price

$173.59

Market Cap

10.5B

Sector

Health Care

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$309.10

Market Cap

8.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENSG
PRAX
Founded
1999
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5B
8.8B
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
ENSG
PRAX
Price
$173.59
$309.10
Analyst Decision
Buy
Strong Buy
Analyst Count
5
15
Target Price
$196.40
$503.93
AVG Volume (30 Days)
325.0K
599.2K
Earning Date
02-04-2026
02-27-2026
Dividend Yield
0.15%
N/A
EPS Growth
35.03
N/A
EPS
5.59
N/A
Revenue
$4,829,467,000.00
$7,463,000.00
Revenue This Year
$21.25
N/A
Revenue Next Year
$12.54
$15,003.90
P/E Ratio
$30.87
N/A
Revenue Growth
17.55
364.98
52 Week Low
$118.73
$26.70
52 Week High
$194.00
$326.91

Technical Indicators

Market Signals
Indicator
ENSG
PRAX
Relative Strength Index (RSI) 46.38 57.00
Support Level $167.43 $304.03
Resistance Level $172.29 $323.40
Average True Range (ATR) 4.81 19.01
MACD -0.43 -2.11
Stochastic Oscillator 36.61 63.51

Price Performance

Historical Comparison
ENSG
PRAX

About ENSG The Ensign Group Inc.

Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Share on Social Networks: